Endocrine Abstracts

Introduction: Acromegaly is a rare disease of the pituitary gland. Both GH and IGF-1 levels are of key importance for monitoring of treatment effects in patients with acromegaly. In some patients, divergent results of measurements of these hormones are observed. Purpose: The purpose of the study was to estimate frequency of GH and IGF-1 inconsistencies in the population of patients with acromegaly included in the Polish Register of Acromegaly Patients, a...

IntroductionTreatment of choice in acromegaly is transsphenoidal resection of GH-secreting pituitary adenoma. Its efficacy ranges from 28% to 83% depending on tumor size and location. Random GH < 1 µg/l or nadir GH in OGTT < 0.4 µg/l and normal IGF-1 are found to be the evidence of effective surgery. However, some patients diagnosed with acromegaly remission after surgery present discordant GH and IGF-1 results.Ai...

Background: The first-line treatment in acromegaly is transsphenoidal adenomectomy of GH-secreting pituitary tumor. Pathologic evaluation of postoperative tissue is an essential part of patient’s assessment.Aim: The aim of this study was to analyse pathologic characteristics of pituitary tumors in patients with acromegaly.Patients and methods: One hundred twenty patients with acromegaly after at least one pituitary surgery tre...

Background: Transsphenoidal adenomectomy of GH-secreting pituitary tumour is a first-line treatment of acromegaly. Pharmacological treatment is recommended if surgery did not lead to disease remission. Pathological assessment of postoperative tissue provides clinicians with valuable information on the disease course.Aim: The aim of this study was to assess whether clinical, imaging, and pathological characteristics can predict surgical remission and resp...